Boardroom Alpha
Start trial
8-K primary document
PRGO · Current Report (Form 8-K) · Filed June 30, 2026

Perrigo Co PLC — 8-K exhibit

a202606-perrigopressreleas.htm
Perrigo Co PLC on Boardroom Alpha
Document

EXHIBIT 99.1
perrigoimagenew.jpg


Perrigo Announces Appointment of Two New Independent Directors to Board

Dublin, Ireland – June 30, 2026 – Perrigo Company plc (NYSE: PRGO) ("Perrigo"), a leading provider of consumer health products, today announced that its Board of Directors has appointed Salman Amin and Omer Gajial as independent directors, effective June 30, 2026.

“We are pleased to welcome Salman and Omer to Perrigo’s Board,” said Orlando D. Ashford, Chair of Perrigo's Board of Directors. “Both bring deep experience across consumer products, retail, and digital transformation, along with a strong track record of driving growth and operational excellence. Their perspective will be valuable as we continue to advance Perrigo’s strategic priorities.”

Salman Amin

Mr. Amin, age 66, is an experienced executive with more than 30 years in the global consumer products industry. He most recently served as Chief Executive Officer of pladis Global, where he led a multi-year transformation that delivered sustained revenue growth and improved profitability.
Previously, Mr. Amin served as Chief Operating Officer of the Global Commercial Division at SC Johnson and held senior leadership roles at PepsiCo and Procter & Gamble.

Omer Gajial

Mr. Gajial, age 52, is a seasoned executive with extensive experience in retail, e-commerce and consumer health. He currently serves as Chief Executive Officer of GoTo Foods, a franchisor and operator of more than 7,000 restaurant and retail locations globally across multiple brands.
Prior to this role, Mr. Gajial served as Executive Vice President and Chief Merchandising & Digital Officer at Albertsons Companies.

About Perrigo

Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.

Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.

For more information, visit www.perrigo.com.



Forward-Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding Perrigo’s expectations about the contributions of its new directors and the advancement of its strategic priorities. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, general economic conditions and other factors described in Perrigo’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent filings. Perrigo undertakes no obligation to update any forward-looking statements, except as required by law.

Perrigo Contacts

Eric Jacobson, Vice President, Global Investor Relations
eric.jacobson@perrigo.com

Nick Gallagher, Associate Director, Global Investor Relations
nicholas.gallagher@perrigo.com

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer